Truvestments Capital’s Protalix BioTherapeutics PLX Stock Holding History

Truvestments Capital’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,458	Closed	-$5.46K	–	1091
2025 Q3	$5.46K	Hold	2,458	–	–	﹤0.01%	802
2025 Q2	$3.64K	Hold	2,458	–	–	﹤0.01%	777
2025 Q1	$6.29K	Hold	2,458	–	–	﹤0.01%	727
2024 Q4	$4.62K	Hold	2,458	–	–	﹤0.01%	709
2024 Q3	$2.51K	Buy	+2,458	New	+$2.58K	﹤0.01%	770
2024 Q2	–	Sell	-3,880	Closed	-$4.89K	–	553
2024 Q1	$4.89K	Hold	3,880	–	–	﹤0.01%	555
2023 Q4	$6.91K	Hold	3,880	–	–	﹤0.01%	554
2023 Q3	$6.44K	Hold	3,880	–	–	﹤0.01%	486
2023 Q2	$7.76K	Hold	3,880	–	–	﹤0.01%	475
2023 Q1	$8.15K	Buy	+3,880	New	+$6.81K	﹤0.01%	455

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Truvestments Capital's PLX Position: Q4 2025 in Review

Truvestments Capital sold out of Protalix BioTherapeutics (PLX) in Q4 2025, closing a stake of 2,458 shares — an estimated $5.46K sold.

Truvestments Capital first reported a position in PLX in Q1 2023 and held it in 10 quarters. The position peaked at $8.15K in Q1 2023. 83 funds tracked by Wall St. Rank hold PLX as of Q4 2025.

Truvestments Capital reported no remaining Protalix BioTherapeutics position as of Q4 2025 after selling out during the quarter.
Truvestments Capital sold 2,458 Protalix BioTherapeutics shares in Q4 2025, an estimated $5.46K.
Truvestments Capital first reported a position in Protalix BioTherapeutics in Q1 2023 and held it in 10 quarters.
Truvestments Capital's Protalix BioTherapeutics position peaked at $8.15K in Q1 2023.
83 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2025.

Based on Truvestments Capital's 13F filing for Q4 2025, filed 13 Feb 2026.